Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 234

1.

Papillary Renal Neoplasm With Reverse Polarity: A Morphologic, Immunohistochemical, and Molecular Study.

Al-Obaidy KI, Eble JN, Cheng L, Williamson SR, Sakr WA, Gupta N, Idrees MT, Grignon DJ.

Am J Surg Pathol. 2019 May 22. doi: 10.1097/PAS.0000000000001288. [Epub ahead of print]

PMID:
31135486
2.

Effect of Perivascular Injection of Botulinum Toxin Type A versus Lidocaine in Survival of Random Pattern Flaps in a Rat Model.

El Shaer WM, Ahmed AEE, Sakr WM, Hawas EM, Fathi MZ.

Plast Reconstr Surg. 2019 Mar;143(3):527e-533e. doi: 10.1097/PRS.0000000000005337.

PMID:
30817649
3.

Tackling tumor heterogeneity and phenotypic plasticity in cancer precision medicine: our experience and a literature review.

Sheng S, Margarida Bernardo M, Dzinic SH, Chen K, Heath EI, Sakr WA.

Cancer Metastasis Rev. 2018 Dec;37(4):655-663. doi: 10.1007/s10555-018-9767-4. Review.

PMID:
30484007
4.

Overexpression of the Pluripotent Stem Cell Marker Podocalyxin in Prostate Cancer.

Heath EI, Heilbrun LK, Smith D, Schopperle WM, Ju Y, Bolton S, Ahmed Q, Sakr WA.

Anticancer Res. 2018 Nov;38(11):6361-6366. doi: 10.21873/anticanres.12994.

PMID:
30396958
5.

Exogenous IL-6 induces mRNA splice variant MBD2_v2 to promote stemness in TP53 wild-type, African American PCa cells.

Teslow EA, Bao B, Dyson G, Legendre C, Mitrea C, Sakr W, Carpten JD, Powell I, Bollig-Fischer A.

Mol Oncol. 2018 Jun;12(7):1138-1152. doi: 10.1002/1878-0261.12316. Epub 2018 May 24.

6.

Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921.

Hussain M, Tangen CM, Thompson IM Jr, Swanson GP, Wood DP, Sakr W, Dawson NA, Haas NB, Flaig TW, Dorff TB, Lin DW, Crawford ED, Quinn DI, Vogelzang NJ, Glode LM.

J Clin Oncol. 2018 May 20;36(15):1498-1504. doi: 10.1200/JCO.2017.76.4126. Epub 2018 Apr 6.

7.

Early Surgery Confers 1-Year Mortality Benefit in Hip-Fracture Patients.

Maheshwari K, Planchard J, You J, Sakr WA, George J, Higuera-Rueda CA, Saager L, Turan A, Kurz A.

J Orthop Trauma. 2018 Mar;32(3):105-110. doi: 10.1097/BOT.0000000000001043.

PMID:
29065037
8.

HPV-associated differential regulation of tumor metabolism in oropharyngeal head and neck cancer.

Jung YS, Najy AJ, Huang W, Sethi S, Snyder M, Sakr W, Dyson G, Hüttemann M, Lee I, Ali-Fehmi R, Franceschi S, Struijk L, Kim HE, Kato I, Kim HC.

Oncotarget. 2017 May 16;8(31):51530-51541. doi: 10.18632/oncotarget.17887. eCollection 2017 Aug 1.

9.

An Essential Role of Maspin in Embryogenesis and Tumor Suppression-Response.

Zhang M, Hendrix MJC, Pemberton PA, Sakr WA, Sheng S.

Cancer Res. 2017 Sep 15;77(18):5208-5210. doi: 10.1158/0008-5472.CAN-17-1254. Epub 2017 Sep 6. No abstract available.

10.

An Essential Role of Maspin in Embryogenesis and Tumor Suppression.

Dzinic SH, Bernardo MM, Li X, Fernandez-Valdivia R, Ho YS, Mi QS, Bandyopadhyay S, Lonardo F, Vranic S, Oliveira DS, Bonfil RD, Dyson G, Chen K, Omerovic A, Sheng X, Han X, Wu D, Bi X, Cabaravdic D, Jakupovic U, Wahba M, Pang A, Harajli D, Sakr WA, Sheng S.

Cancer Res. 2017 Feb 15;77(4):886-896. doi: 10.1158/0008-5472.CAN-16-2219. Epub 2016 Dec 6.

11.

Anti-androgenic activity of absorption-enhanced 3, 3'-diindolylmethane in prostatectomy patients.

Hwang C, Sethi S, Heilbrun LK, Gupta NS, Chitale DA, Sakr WA, Menon M, Peabody JO, Smith DW, Sarkar FH, Heath EI.

Am J Transl Res. 2016 Jan 15;8(1):166-76. eCollection 2016.

12.

Comparative Histological Study on the Therapeutic Effect of Green Tea and Stem Cells in Alzheimer's Disease Complicating Experimentally Induced Diabetes.

Bassiony HS, Zickri MB, Metwally HG, Elsherif HA, Alghandour SM, Sakr W.

Int J Stem Cells. 2015 Nov;8(2):181-90. doi: 10.15283/ijsc.2015.8.2.181.

13.

Therapeutic Effect of Adipose Derived Stem Cells versus Atorvastatin on Amiodarone Induced Lung Injury in Male Rat.

Aboul-Fotouh GI, Zickri MB, Metwally HG, Ibrahim IR, Kamar SS, Sakr W.

Int J Stem Cells. 2015 Nov;8(2):170-80. doi: 10.15283/ijsc.2015.8.2.170.

14.

Tumor suppressor maspin as a modulator of host immune response to cancer.

Dzinic SH, Bernardo MM, Oliveira DS, Wahba M, Sakr W, Sheng S.

Bosn J Basic Med Sci. 2015 Oct 25;15(4):1-6. doi: 10.17305/bjbms.2015.783. Review.

15.

Maspin Expression in Prostate Tumor Cells Averts Stemness and Stratifies Drug Sensitivity.

Bernardo MM, Kaplun A, Dzinic SH, Li X, Irish J, Mujagic A, Jakupovic B, Back JB, Van Buren E, Han X, Dean I, Chen YQ, Heath E, Sakr W, Sheng S.

Cancer Res. 2015 Sep 15;75(18):3970-9. doi: 10.1158/0008-5472.CAN-15-0234. Epub 2015 Jul 24.

16.

A severe interaction between Tizanidine and Ciprofloxacin.

Abd-Elsayed A, Elsharkawy H, Sakr W.

J Clin Anesth. 2015 Dec;27(8):698. doi: 10.1016/j.jclinane.2015.05.016. Epub 2015 Jun 29. No abstract available.

PMID:
26138629
17.

Maspin expression in prostate tumor elicits host anti-tumor immunity.

Dzinic SH, Chen K, Thakur A, Kaplun A, Bonfil RD, Li X, Liu J, Bernardo MM, Saliganan A, Back JB, Yano H, Schalk DL, Tomaszewski EN, Beydoun AS, Dyson G, Mujagic A, Krass D, Dean I, Mi QS, Heath E, Sakr W, Lum LG, Sheng S.

Oncotarget. 2014 Nov 30;5(22):11225-36.

18.

Androgen receptor splice variants contribute to prostate cancer aggressiveness through induction of EMT and expression of stem cell marker genes.

Kong D, Sethi S, Li Y, Chen W, Sakr WA, Heath E, Sarkar FH.

Prostate. 2015 Feb;75(2):161-74. doi: 10.1002/pros.22901. Epub 2014 Oct 13.

19.

Erratum: Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatment.

Kong D, Heath E, Chen W, Cher M, Powell I, Heilbrun L, Li Y, Ali S, Sethi S, Hassan O, Hwang C, Gupta N, Chitale D, Sakr W, Menon M, Sarkar F.

Am J Transl Res. 2013 Dec 1;6(1):102-103. eCollection 2013.

20.

Transcriptional regulation of CXCR4 in prostate cancer: significance of TMPRSS2-ERG fusions.

Singareddy R, Semaan L, Conley-Lacomb MK, St John J, Powell K, Iyer M, Smith D, Heilbrun LK, Shi D, Sakr W, Cher ML, Chinni SR.

Mol Cancer Res. 2013 Nov;11(11):1349-61. doi: 10.1158/1541-7786.MCR-12-0705. Epub 2013 Aug 5.

21.

[Acute transverse myelitis and Lyme borreliosis: a case report].

Gaudichon J, Sakr W, Becher S, Linard M, Kozisek S.

Arch Pediatr. 2013 Jun;20(6):646-9. doi: 10.1016/j.arcped.2013.03.025. Epub 2013 Apr 28. French.

PMID:
23628118
22.

SWOG S0353: Phase II trial of intravesical gemcitabine in patients with nonmuscle invasive bladder cancer and recurrence after 2 prior courses of intravesical bacillus Calmette-Guérin.

Skinner EC, Goldman B, Sakr WA, Petrylak DP, Lenz HJ, Lee CT, Wilson SS, Benson M, Lerner SP, Tangen CM, Thompson IM.

J Urol. 2013 Oct;190(4):1200-4. doi: 10.1016/j.juro.2013.04.031. Epub 2013 Apr 15.

23.

Comprehensive molecular oncogenomic profiling and miRNA analysis of prostate cancer.

Sethi S, Kong D, Land S, Dyson G, Sakr WA, Sarkar FH.

Am J Transl Res. 2013;5(2):200-11. Epub 2013 Mar 28.

24.

3, 3'-Diindolylmethane enhances the effectiveness of herceptin against HER-2/neu-expressing breast cancer cells.

Ahmad A, Ali S, Ahmed A, Ali AS, Raz A, Sakr WA, Rahman KM.

PLoS One. 2013;8(1):e54657. doi: 10.1371/journal.pone.0054657. Epub 2013 Jan 22.

25.
26.

Maspin reprograms the gene expression profile of prostate carcinoma cells for differentiation.

Bernardo MM, Meng Y, Lockett J, Dyson G, Dombkowski A, Kaplun A, Li X, Yin S, Dzinic S, Olive M, Dean I, Krass D, Moin K, Bonfil RD, Cher M, Sakr W, Sheng S.

Genes Cancer. 2011 Nov;2(11):1009-22. doi: 10.1177/1947601912440170.

27.

Loss of let-7 up-regulates EZH2 in prostate cancer consistent with the acquisition of cancer stem cell signatures that are attenuated by BR-DIM.

Kong D, Heath E, Chen W, Cher ML, Powell I, Heilbrun L, Li Y, Ali S, Sethi S, Hassan O, Hwang C, Gupta N, Chitale D, Sakr WA, Menon M, Sarkar FH.

PLoS One. 2012;7(3):e33729. doi: 10.1371/journal.pone.0033729. Epub 2012 Mar 19.

28.

Epigenetic silencing of miR-34a in human prostate cancer cells and tumor tissue specimens can be reversed by BR-DIM treatment.

Kong D, Heath E, Chen W, Cher M, Powell I, Heilbrun L, Li Y, Ali S, Sethi S, Hassan O, Hwang C, Gupta N, Chitale D, Sakr WA, Menon M, Sarkar FH.

Am J Transl Res. 2012;4(1):14-23. Epub 2012 Jan 5. Erratum in: Am J Transl Res. 2013 Dec 01;6(1):102-103.

29.

Upgrading wet granulation monitoring from hand squeeze test to mixing torque rheometry.

Sakr WF, Ibrahim MA, Alanazi FK, Sakr AA.

Saudi Pharm J. 2012 Jan;20(1):9-19. doi: 10.1016/j.jsps.2011.04.007. Epub 2011 May 7.

30.

Novel targets for detection of cancer and their modulation by chemopreventive natural compounds.

Ahmad A, Sakr WA, Rahman KM.

Front Biosci (Elite Ed). 2012 Jan 1;4:410-25. Review.

PMID:
22201883
31.

Intravascular papillary endothelial hyperplasia of the bladder: Case report and review of the literature.

Jazaerly T, Jaratli H, Sakr W, Almardini N, Urabi M, Dhar N, Giorgadze T.

Avicenna J Med. 2011 Oct;1(2):55-7. doi: 10.4103/2231-0770.90917.

32.

Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917.

Marshall JR, Tangen CM, Sakr WA, Wood DP Jr, Berry DL, Klein EA, Lippman SM, Parnes HL, Alberts DS, Jarrard DF, Lee WR, Gaziano JM, Crawford ED, Ely B, Ray M, Davis W, Minasian LM, Thompson IM Jr.

Cancer Prev Res (Phila). 2011 Nov;4(11):1761-9. doi: 10.1158/1940-6207.CAPR-10-0343. Epub 2011 Sep 6.

33.

Molecular markers of epithelial-to-mesenchymal transition are associated with tumor aggressiveness in breast carcinoma.

Sethi S, Sarkar FH, Ahmed Q, Bandyopadhyay S, Nahleh ZA, Semaan A, Sakr W, Munkarah A, Ali-Fehmi R.

Transl Oncol. 2011 Aug;4(4):222-6. Epub 2011 Aug 1.

34.

HDAC1 inhibition by maspin abrogates epigenetic silencing of glutathione S-transferase pi in prostate carcinoma cells.

Li X, Kaplun A, Lonardo F, Heath E, Sarkar FH, Irish J, Sakr W, Sheng S.

Mol Cancer Res. 2011 Jun;9(6):733-45. doi: 10.1158/1541-7786.MCR-10-0505. Epub 2011 May 26.

35.

Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study.

Dorff TB, Flaig TW, Tangen CM, Hussain MH, Swanson GP, Wood DP Jr, Sakr WA, Dawson NA, Haas NB, Crawford ED, Vogelzang NJ, Thompson IM, Glode LM.

J Clin Oncol. 2011 May 20;29(15):2040-5. doi: 10.1200/JCO.2010.32.2776. Epub 2011 Apr 18.

36.

Manual and automated systems in the analysis of images from prostate tissue microarray cores.

Singh SS, Ray MJ, Davis W, Marshall JR, Sakr WA, Mohler JL.

Anal Quant Cytol Histol. 2010 Dec;32(6):311-9.

PMID:
21456342
37.

Mechanisms and therapeutic implications of cell death induction by indole compounds.

Ahmad A, Sakr WA, Rahman KW.

Cancers (Basel). 2011 Jul 19;3(3):2955-74. doi: 10.3390/cancers3032955.

38.

Effect of Kollidon® SR on the release of Albuterol Sulphate from matrix tablets.

Sakr W, Alanazi F, Sakr A.

Saudi Pharm J. 2011 Jan;19(1):19-27. doi: 10.1016/j.jsps.2010.11.002. Epub 2010 Nov 4.

39.

3,3'-Diindolylmethane enhances taxotere-induced growth inhibition of breast cancer cells through downregulation of FoxM1.

Ahmad A, Ali S, Wang Z, Ali AS, Sethi S, Sakr WA, Raz A, Rahman KM.

Int J Cancer. 2011 Oct 1;129(7):1781-91. doi: 10.1002/ijc.25839. Epub 2011 Mar 8. Erratum in: Int J Cancer. 2014 Nov 1;135(9):E10.

40.

Tocilizumab: A new anti-rheumatic drug.

Abou-Auda HS, Sakr W.

Saudi Pharm J. 2010 Oct;18(4):257-9. doi: 10.1016/j.jsps.2010.07.009. Epub 2010 Aug 3. No abstract available.

41.
42.

Anticancer properties of indole compounds: mechanism of apoptosis induction and role in chemotherapy.

Ahmad A, Sakr WA, Rahman KM.

Curr Drug Targets. 2010 Jun;11(6):652-66. Review.

PMID:
20298156
43.

3,3'-Diindolylmethane enhances taxotere-induced apoptosis in hormone-refractory prostate cancer cells through survivin down-regulation.

Rahman KM, Banerjee S, Ali S, Ahmad A, Wang Z, Kong D, Sakr WA.

Cancer Res. 2009 May 15;69(10):4468-75. doi: 10.1158/0008-5472.CAN-08-4423. Epub 2009 May 12.

44.

Grading of invasive cribriform carcinoma on prostate needle biopsy: an interobserver study among experts in genitourinary pathology.

Latour M, Amin MB, Billis A, Egevad L, Grignon DJ, Humphrey PA, Reuter VE, Sakr WA, Srigley JR, Wheeler TM, Yang XJ, Epstein JI.

Am J Surg Pathol. 2008 Oct;32(10):1532-9. doi: 10.1097/PAS.0b013e318169e8fd.

PMID:
18724248
45.

Treatment options for muscle-invasive urothelial cancer for patients who were not eligible for cystectomy or neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin: report of Southwest Oncology Group Trial 8733.

Higano CS, Tangen CM, Sakr WA, Faulkner J, Rivkin SE, Meyers FJ, Hussain M, Baker LH, Russell KJ, Crawford ED; Southwest Oncology Group Trial 8733.

Cancer. 2008 May 15;112(10):2181-7. doi: 10.1002/cncr.23420.

46.

The effect of race/ethnicity on the accuracy of the 2001 Partin Tables for predicting pathologic stage of localized prostate cancer.

Heath EI, Kattan MW, Powell IJ, Sakr W, Brand TC, Rybicki BA, Thompson IM, Aronson WJ, Terris MK, Kane CJ, Presti JC Jr, Amling CL, Freedland SJ.

Urology. 2008 Jan;71(1):151-5. doi: 10.1016/j.urology.2007.08.016.

PMID:
18242385
48.

Health issues in the Arab American community. Global health from Arab and developing world perspectives. Overview.

Sakr WA, Akil N.

Ethn Dis. 2007 Summer;17(2 Suppl 3):S3-50. No abstract available.

PMID:
17985452
49.

Health issues in the Arab American community. Highlights of conference keynote presentations.

Hammad A, Darwish-Yassine M, Sakr WA.

Ethn Dis. 2007 Summer;17(2 Suppl 3):S3-3-S3-5. No abstract available.

PMID:
17983005
50.

Transoral carbon dioxide laser supraglottic laryngectomy and irradiation in stage I, II, and III squamous cell carcinoma of the supraglottic larynx: report of Southwest Oncology Group Phase 2 Trial S9709.

Agrawal A, Moon J, Davis RK, Sakr WA, Giri SP, Valentino J, LeBlanc M, Truelson JM, Yoo GH, Ensley JF, Schuller DE; Southwest Oncology Group.

Arch Otolaryngol Head Neck Surg. 2007 Oct;133(10):1044-50.

PMID:
17938330

Supplemental Content

Support Center